GoBear is now part of Finder
Picture not described

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Pfizer (PFE) shares

Learn how to easily invest in Pfizer shares.

Pfizer Inc is a drug manufacturers-general business based in the US. Pfizer shares (PFE) are listed on the NYSE and all prices are listed in US Dollars. Pfizer employs 78,500 staff and has a trailing 12-month revenue of around USD$55.5 billion.

How to buy shares in Pfizer

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PFE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Compare online brokers

Name Product Number of Stocks Shares Available Markets
Interactive Brokers
Access to global markets
Yes
Global markets
Your capital is at risk.
Saxo Markets
19,000+
Yes
Global markets
Your capital is at risk.
Plus500
2,000+
No
US, UK, AU, DE, FR, IT, PT, GR, JP, SG, ZA, NL, FI, BE, DK, SE, CH, ES, AT, NO, HU, CZ, IE, PL, HK
CFD Service. Your capital is at risk.
BlackBull Markets
N/A
No
UK, HK, JP, MY, NZ, US
CFD Service. Your capital is at risk.
Libertex
50+
No
Worldwide with exception.
Except for: US/Australia/New Zealand/Belgium/British Virgin Islands/Guam/Lebanon/United States Minor/Outlying Islands/Northern Mariana Islands/Uganda/Philippines/Sri Lanka/Kuwait/South Africa/Azerbaijan/Canada/Armenia/Russia/Japan/Brasil.
CFD Service. Your capital is at risk.
Exness
N/A
No
CH, VN, TH, PH, SG, ID, IN, UAE, ZA, SA, EG, BR, CR, MX
CFD Service. Your capital is at risk.
IG
17,000+
No
DK, IE, NO, RU, DE, IT, AT, CH, ES, LU, PT, SE, FR, NL, RO, UK, US, AU, JP, SG, ZA, AE
CFD Service. Your capital is at risk.
loading

Compare up to 4 providers

How has Coronavirus impacted Pfizer's stock price?

Since the stock market crash in March caused by coronavirus, Pfizer's stock price has had significant positive movement.

Its last market close was $43.89, which is 18.61% up on its pre-crash value of $35.72 and 57.42% up on the lowest point reached during the March crash when the stocks fell as low as $27.88.

If you had bought $1,000 worth of Pfizer stocks at the start of February 2020, those stocks would have been worth $759.54 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,170.11.

Is it a good time to buy Pfizer stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pfizer shares at a glance

Information last updated 2021-09-17.
Latest market close$43.89
52-week range$31.76 - $51.86
50-day moving average $46.53
200-day moving average $40.41
Wall St. target price$46.03
PE ratio 18.7404
Dividend yield $1.54 (3.46%)
Earnings per share (TTM) $2.34

Pfizer stock price (NYSE: PFE)

Use our graph to track the performance of PFE stocks over time.

Pfizer price performance over time

Historical closes compared with the close of $43.89 from 2021-09-17

1 week (2021-09-10) -3.73%
1 month (2021-08-18) 12.08%
3 months (2021-06-18) 13.09%
6 months (2021-03-18) 22.70%
1 year (2020-09-18) 19.82%
2 years (2019-09-18) 20.64%
3 years (2018-09-18) 0.87%
5 years (2016-09-16) 29.32%

Is Pfizer under- or over-valued?

Valuing Pfizer stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pfizer's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Pfizer's P/E ratio

Pfizer's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Pfizer shares trade at around 19x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Pfizer's PEG ratio

Pfizer's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.9255. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Pfizer's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Pfizer's EBITDA

Pfizer's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $20.1 billion.

The EBITDA is a measure of a Pfizer's overall financial performance and is widely used to measure a its profitability.

Pfizer financials

Revenue TTM $55.5 billion
Operating margin TTM 27.32%
Gross profit TTM $33.3 billion
Return on assets TTM 5.45%
Return on equity TTM 18.35%
Profit margin 23.8%
Book value $12.51
Market capitalisation $246.1 billion

TTM: trailing 12 months

Shorting Pfizer shares

There are currently 58.7 million Pfizer shares held short by investors – that's known as Pfizer's "short interest". This figure is 7.7% up from 54.5 million last month.

There are a few different ways that this level of interest in shorting Pfizer shares can be evaluated.

Pfizer's "short interest ratio" (SIR)

Pfizer's "short interest ratio" (SIR) is the quantity of Pfizer shares currently shorted divided by the average quantity of Pfizer shares traded daily (recently around 45.8 million). Pfizer's SIR currently stands at 1.28. In other words for every 100,000 Pfizer shares traded daily on the market, roughly 1280 shares are currently held short.

However Pfizer's short interest can also be evaluated against the total number of Pfizer shares, or, against the total number of tradable Pfizer shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pfizer's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Pfizer shares in existence, roughly 10 shares are currently held short) or 0.0105% of the tradable shares (for every 100,000 tradable Pfizer shares, roughly 11 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pfizer.

Pfizer's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Pfizer.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Pfizer's total ESG risk score

Total ESG risk: 33.15

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Pfizer's overall score of 33.15 (as at 12/31/2018) is pretty weak – landing it in it in the 60th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Pfizer is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Pfizer's environmental score

Environmental score: 7/100

Pfizer's environmental score of 7 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Pfizer's social score

Social score: 18.47/100

Pfizer's social score of 18.47 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Pfizer's governance score

Governance score: 13.68/100

Pfizer's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Pfizer is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Pfizer's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Pfizer scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Pfizer hasn't always managed to keep its nose clean.

Pfizer share dividends

49%

Dividend payout ratio: 48.73% of net profits

Recently Pfizer has paid out, on average, around 48.73% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.51% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Pfizer shareholders could enjoy a 3.51% return on their shares, in the form of dividend payments. In Pfizer's case, that would currently equate to about $1.54 per share.

While Pfizer's payout ratio might seem fairly standard, it's worth remembering that Pfizer may be investing much of the rest of its net profits in future growth.

Pfizer's most recent dividend payout was on 6 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 28 July 2021 (the "ex-dividend date").

Have Pfizer's shares ever split?

Pfizer's shares were split on a 1054:1000 basis on 16 November 2020. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1054 shares. This wouldn't directly have changed the overall worth of your Pfizer shares – just the quantity. However, indirectly, the new 5.1% lower share price could have impacted the market appetite for Pfizer shares which in turn could have impacted Pfizer's share price.

Pfizer share price volatility

Over the last 12 months, Pfizer's shares have ranged in value from as little as $31.7629 up to $51.86. A popular way to gauge a stock's volatility is its "beta".

PFE.US volatility(beta: 0.68)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Pfizer's is 0.679. This would suggest that Pfizer's shares are less volatile than average (for this exchange).

Pfizer overview

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask Finder

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked
Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy Policy and Terms.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site